Charles River Laboratories (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 465,411 | 228,424 | 242,879 | 402,020 | 372,433 |
| Receivables | 610,566 | 617,740 | 572,058 | 532,531 | 542,390 |
| Inventories | 193,584 | 185,695 | 181,367 | 168,366 | 162,938 |
| Other current assets | 71,922 | 72,560 | 74,489 | 65,062 | 61,694 |
| TOTAL | $1,423,209 | $1,201,131 | $1,140,274 | $1,234,725 | $1,208,281 |
| Non-Current Assets | |||||
| PPE Net | 1,117,003 | 1,124,358 | 1,037,212 | 1,028,005 | 1,033,409 |
| Intangibles | 1,973,811 | 1,875,262 | 1,848,012 | 1,809,611 | 1,812,184 |
| Other Non-Current Assets | 1,294,940 | 1,290,080 | 1,187,840 | 1,168,543 | 1,147,916 |
| TOTAL | $4,385,754 | $4,289,700 | $4,073,064 | $4,006,159 | $3,993,509 |
| Total Assets | $5,808,963 | $5,490,831 | $5,213,338 | $5,240,884 | $5,201,790 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 2,932 | 50,214 | 47,946 | 53,713 | 47,667 |
| Accounts payable and accrued liabilities | 127,129 | 122,475 | 96,758 | 82,978 | 102,697 |
| Accrued Expenses | 362,936 | 356,643 | 342,356 | 312,196 | 252,783 |
| Other current liabilities | 97,347 | 102,477 | 127,618 | 108,639 | 108,920 |
| TOTAL | $803,376 | $839,751 | $787,014 | $727,936 | $690,896 |
| Non-Current Liabilities | |||||
| Long Term Debt | 2,202,334 | 1,929,571 | 1,968,161 | 2,207,157 | 2,326,770 |
| Deferred Revenues | 213,032 | 207,942 | 172,336 | 170,410 | 178,829 |
| Other Non-Current Liabilities | 405,653 | 385,310 | 354,604 | 347,041 | 331,335 |
| TOTAL | $2,817,403 | $2,532,911 | $2,524,859 | $2,756,223 | $2,855,267 |
| Total Liabilities | $3,620,779 | $3,372,662 | $3,311,873 | $3,484,159 | $3,546,163 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 50,253 | 49,776 | 49,743 | 49,679 | 49,487 |
| Common Shares | 504 | 498 | 499 | 498 | 496 |
| Retained earnings | 686,944 | 625,414 | 501,442 | 398,533 | 331,098 |
| Other shareholders' equity | -122,788 | -135,307 | -190,661 | -208,423 | -214,949 |
| TOTAL | $2,188,184 | $2,118,169 | $1,901,465 | $1,756,725 | $1,655,627 |
| Total Liabilities And Equity | $5,808,963 | $5,490,831 | $5,213,338 | $5,240,884 | $5,201,790 |